AAP
KZIA

Arax Advisory Partners’s Kazia Therapeutics KZIA Stock Holding History

Arax Advisory Partners’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$1.38K – 4096
2025
Q4 		$1.38K Hold
200
– – ﹤0.01% 3394
2025
Q3 		$1.44K Hold
200
– – ﹤0.01% 3178
2025
Q2 		$1.25K Hold
200
– – ﹤0.01% 2712
2025
Q1 		$783 Buy
+200
New +$1.18K ﹤0.01% 2391

Other funds holding KZIA

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arax Advisory Partners's KZIA Position: Q1 2026 in Review

Arax Advisory Partners sold out of Kazia Therapeutics (KZIA) in Q1 2026, closing a stake of 200 shares — an estimated $1.38K sold.

Arax Advisory Partners first reported a position in KZIA in Q1 2025 and held it in 4 quarters. The position peaked at $1.44K in Q3 2025. 23 funds tracked by Wall St. Rank hold KZIA as of Q1 2026.

  • Arax Advisory Partners reported no remaining Kazia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 200 Kazia Therapeutics shares in Q1 2026, an estimated $1.38K.
  • Arax Advisory Partners first reported a position in Kazia Therapeutics in Q1 2025 and held it in 4 quarters.
  • Arax Advisory Partners's Kazia Therapeutics position peaked at $1.44K in Q3 2025.
  • 23 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.